Loading...
XNYSJNJ
Market cap347bUSD
Dec 20, Last price  
144.47USD
1D
0.62%
1Q
-11.99%
Jan 2017
25.40%
Name

Johnson & Johnson

Chart & Performance

D1W1MN
XNYS:JNJ chart
P/E
9.89
P/S
4.08
EPS
14.60
Div Yield, %
3.38%
Shrs. gr., 5y
-1.27%
Rev. gr., 5y
0.86%
Revenues
85.16b
+6.46%
47,348,000,00050,514,000,00053,324,000,00061,095,000,00063,747,000,00061,897,000,00061,587,000,00065,030,000,00067,224,000,00071,312,000,00074,331,000,00070,074,000,00071,890,000,00076,450,000,00081,581,000,00082,059,000,00082,584,000,00078,740,000,00079,990,000,00085,159,000,000
Net income
35.15b
+95.94%
8,509,000,00010,411,000,00011,053,000,00010,576,000,00012,949,000,00012,266,000,00013,334,000,0009,672,000,00010,853,000,00013,831,000,00016,323,000,00015,409,000,00016,540,000,0001,300,000,00015,297,000,00015,119,000,00014,714,000,00020,878,000,00017,941,000,00035,153,000,000
CFO
22.79b
+7.54%
11,131,000,00011,877,000,00014,248,000,00015,249,000,00014,972,000,00016,571,000,00016,385,000,00014,298,000,00015,396,000,00017,414,000,00018,471,000,00019,279,000,00018,767,000,00021,056,000,00022,201,000,00023,416,000,00023,536,000,00023,410,000,00021,194,000,00022,791,000,000
Dividend
Aug 27, 20241.24 USD/sh
Earnings
Jan 22, 2025

Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
URL
https://www.jnj.com/
IPO date
Sep 25, 1944
Employees
152,700
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122023‑002022‑002021‑002019‑122018‑122017‑122017‑002016‑002014‑12
Income
Revenues
85,159,000
8.15%
79,990,000
1.59%
78,740,000
-4.65%
Cost of revenue
61,750,000
57,777,000
57,797,000
Unusual Expense (Income)
NOPBT
23,409,000
22,213,000
20,943,000
NOPBT Margin
27.49%
27.77%
26.60%
Operating Taxes
1,736,000
2,989,000
1,377,000
Tax Rate
7.42%
13.46%
6.57%
NOPAT
21,673,000
19,224,000
19,566,000
Net income
35,153,000
68.37%
17,941,000
-14.07%
20,878,000
41.89%
Dividends
(11,770,000)
(11,682,000)
(11,032,000)
Dividend yield
2.93%
2.48%
2.41%
Proceeds from repurchase of equity
8,328,000
(4,706,000)
(418,000)
BB yield
-2.08%
1.00%
0.09%
Debt
Debt current
3,451,000
12,756,000
3,766,000
Long-term debt
25,881,000
26,886,000
29,985,000
Deferred revenue
Other long-term liabilities
23,428,000
23,895,000
25,297,000
Net debt
6,405,000
17,361,000
2,143,000
Cash flow
Cash from operating activities
22,791,000
21,194,000
23,410,000
CAPEX
(4,543,000)
(4,009,000)
(3,652,000)
Cash from investing activities
878,000
(12,371,000)
(8,683,000)
Cash from financing activities
(15,825,000)
(8,871,000)
(14,047,000)
FCF
20,737,000
20,204,000
19,370,000
Balance
Cash
22,927,000
22,281,000
31,608,000
Long term investments
Excess cash
18,669,050
18,281,500
27,671,000
Stockholders' equity
144,436,000
118,498,000
113,122,000
Invested Capital
99,871,950
122,059,500
105,400,000
ROIC
21.12%
16.90%
18.44%
ROCE
19.23%
15.39%
14.90%
EV
Common stock shares outstanding
2,560,400
2,663,900
2,674,000
Price
156.74
-8.38%
176.65
3.26%
171.07
8.70%
Market cap
401,317,096
-12.27%
470,577,935
2.87%
457,441,180
8.83%
EV
407,722,096
487,938,935
459,584,180
EBITDA
30,895,000
29,183,000
28,333,000
EV/EBITDA
13.20
16.72
16.22
Interest
772,000
276,000
183,000
Interest/NOPBT
3.30%
1.24%
0.87%